These data suggested that Rg1 could be used as a potential candidate drug to improve the behavioral deficits in AD via modulating the expression of the proteins (i.e., CPLX2, SYN2, and SNP25) involved in memory and depression behaviors. The gene discussed is PPP1R3A; the disease is depressive disorder.